Last update May 19, 2022
Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Suvorexant in other languages or writings:
Main tradenames from several countries containing Suvorexant in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 82 | % |
Molecular weight | 451 | daltons |
Protein Binding | > 99 | % |
VD | 0.7 | l/Kg |
Tmax | 2 | hours |
T½ | 12 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Suvorexant is a dual orexin receptor antagonist used to treat insomnia in adults. Oral administration in one dose at bedtime.
At the date of the last update we did not find any published data on its excretion in breast milk.
Its pharmacokinetic characteristics (very high plasma protein binding, moderately elevated molecular weight and large volume of distribution) make it very unlikely its excretion into breast milk in significant amounts.
Infants exposed to this drug through breast milk should be monitored for excessive sedation and/or poor feeding.
It is not recommended to share a bed with the baby if this drug is being taken. (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.